6838 — Formosa Pharmaceuticals Share Price
Last trade - 00:00- TWD5.96bn
- TWD4.96bn
- TWD31.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.9 | ||
| Price to Tang. Book | 9.14 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 44.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.67% | ||
| Return on Equity | -25.27% | ||
| Operating Margin | -169.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 1.13 | n/a | 28.53 | 1.31 | 31.17 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Formosa Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the development of early drug candiate and pre-clinical drug products. The Company also conducts the research and development of nanotechnology platform and dosage form design, and uses the patented nano platform to overcome the challenges of low dissociation rate and poor bioavailability in the development of pharmaceutical dosage forms. In the research and development projects, the ophthalmic drug APP13007 has entered the phase III clinical trial stage, and its indications are anti-ocular postoperative inflammation, and its main appeal is to reduce postoperative inflammation and pain. TSY-0110 has entered the preclinical stage to develop antibody-drug conjugate (ADC) to cure breast cancer. The innovative small molecule compound MPT0E028 has completed the first phase of clinical trials and is expected to be used in the field of anti-cancer therapy.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 6th, 2010
- Public Since
- October 7th, 2021
- No. of Shareholders
- 4,147
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 134,162,100
- Address
- 8F-6, No. 57, Fuxing North Road, TAIPEI, 105
- Web
- https://www.formosapharma.com/
- Phone
- +886 227557659
- Contact
- Jingcheng Wei
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for 6838
Similar to 6838
Adimmune
Taiwan Stock Exchange
Bora Pharmaceuticals Co
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
Chunghwa Chemical Synthesis & Biotech Co
Taiwan Stock Exchange
Formosa Laboratories
Taiwan Stock Exchange
FAQ
As of Today at 20:43 UTC, shares in Formosa Pharmaceuticals are trading at TWD44.45. This share price information is delayed by 15 minutes.
Shares in Formosa Pharmaceuticals last closed at TWD44.45 and the price had moved by -15.01% over the past 365 days. In terms of relative price strength the Formosa Pharmaceuticals share price has underperformed the FTSE Developed Asia Pacific Index by -24.63% over the past year.
There is no consensus recommendation for this security.
Find out moreFormosa Pharmaceuticals does not currently pay a dividend.
Formosa Pharmaceuticals does not currently pay a dividend.
Formosa Pharmaceuticals does not currently pay a dividend.
To buy shares in Formosa Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD44.45, shares in Formosa Pharmaceuticals had a market capitalisation of TWD5.96bn.
Here are the trading details for Formosa Pharmaceuticals:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6838
Based on an overall assessment of its quality, value and momentum Formosa Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Formosa Pharmaceuticals. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -19.34%.
As of the last closing price of TWD44.45, shares in Formosa Pharmaceuticals were trading -13.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Formosa Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD44.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Formosa Pharmaceuticals' directors